

Callie A Scott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11242505/publications.pdf>

Version: 2024-02-01

17
papers

844
citations

687363

13
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1140
citing authors

#	ARTICLE	IF	CITATIONS
1	A framework for evaluating the costs of malaria elimination interventions: an application to reactive case detection in Southern Province of Zambia, 2014. <i>Malaria Journal</i> , 2016, 15, 408.	2.3	14
2	Resource Utilization and Costs of Care prior to ART Initiation for Pediatric Patients in Zambia. <i>AIDS Research and Treatment</i> , 2014, 2014, 1-5.	0.7	5
3	Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study. <i>BMC Public Health</i> , 2014, 14, 296.	2.9	19
4	The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial. <i>Drug and Alcohol Dependence</i> , 2013, 128, 90-97.	3.2	32
5	Could Early Antiretroviral Therapy Entail More Risks than Benefits in Sub-Saharan African HIV-Infected Adults? A Model-Based Analysis. <i>Antiviral Therapy</i> , 2013, 18, 45-55.	1.0	17
6	Retention in Care and Outpatient Costs for Children Receiving Antiretroviral Therapy in Zambia: A Retrospective Cohort Analysis. <i>PLoS ONE</i> , 2013, 8, e67910.	2.5	20
7	Uptake, Outcomes, and Costs of Antenatal, Well-Baby, and Prevention of Mother-to-Child Transmission of HIV Services under Routine Care Conditions in Zambia. <i>PLoS ONE</i> , 2013, 8, e72444.	2.5	14
8	The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. <i>Clinical Infectious Diseases</i> , 2012, 54, 1504-1513.	5.8	85
9	Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. <i>HIV Clinical Trials</i> , 2012, 13, 1-10.	2.0	8
10	The Cost-Effectiveness of Tuberculosis Preventive Therapy for HIV-Infected Individuals in Southern India: A Trial-Based Analysis. <i>PLoS ONE</i> , 2012, 7, e36001.	2.5	26
11	Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. <i>HIV Clinical Trials</i> , 2012, 13, 1-10.	2.0	4
12	Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC. <i>Clinical Infectious Diseases</i> , 2010, 51, 392-400.	5.8	100
13	Cost-effectiveness of Tenofovir as First-Line Antiretroviral Therapy in India. <i>Clinical Infectious Diseases</i> , 2010, 50, 416-425.	5.8	54
14	HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-effectiveness. <i>Clinical Infectious Diseases</i> , 2009, 48, 806-815.	5.8	240
15	The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. <i>Aids</i> , 2008, 22, 2025-2033.	2.2	130
16	Potential Risks and Benefits of HIV Treatment Simplification: A Simulation Model of a Proposed Clinical Trial. <i>Clinical Infectious Diseases</i> , 2007, 45, 1062-1070.	5.8	28
17	Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. <i>Aids</i> , 2007, 21, S117-S128.	2.2	48